Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Assessing the Impact of Genetic Modifications on Chimeric Antigen Receptor (CAR) T-Cell Proliferation Capacity and Persistence
FY 2019-20
Summary
"Cancer is the leading cause of death across the globe. There is substantial research being done to develop a curative treatment with minimal side effects. However, these efforts are challenged by the complexity of cancer cells. They have mechanisms in place that allow them to adapt to their environment and become resistant to many drugs that are currently on the market. Moreover, majority of currently available treatments have serious side effects. It is therefore imperative for us to find new and improved therapeutics. Our research focuses on immunotherapy with the aim of reinforcing our own bodies' immune system response against the spread of these tumour cells. Of particular importance to this project is Chimeric Antigen Receptor (CAR) T-Cell therapy. CAR T-Cells are a type of immune cells derived from patients' own blood, which are then genetically engineered in the laboratory to express receptors that recognize the cancer cells specifically and kill them. This therapy has shown great success in clinical trials; however, its efficacy is hampered by poor proliferation and expansion of the CAR T-Cells after re-administration into patients. In order to overcome this challenge, chemotherapeutic agents are administered beforehand to reduce the host immune cells' response against the treatment, but while also risking damage to the engineered CAR T-Cells. Therefore, our objective is to construct chemotherapy resistant CAR T-Cells and assess their proliferative capacity. Successful modifications of these cells will further enhance their expansion and persistence to ultimately improve their efficacy."
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
428962
Name
Maru Bruktawit
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Assessing the Impact of Genetic Modifications on Chimeric Antigen Receptor (CAR) T-Cell Proliferation Capacity and Persistence
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Lymphoblastic Leukemia; Adaptive T-Cell Expansion And Persistance; Cancer Research; Chimeric Antigen Receptor (Car) T-Cells; Cyclophosphamide Resistance; Genetic Engineering; Immunotherapy; Lymphodepletion; Synthetic Biology
Abstract
"Cancer is the leading cause of death across the globe. There is substantial research being done to develop a curative treatment with minimal side effects. However, these efforts are challenged by the complexity of cancer cells. They have mechanisms in place that allow them to adapt to their environment and become resistant to many drugs that are currently on the market. Moreover, majority of currently available treatments have serious side effects. It is therefore imperative for us to find new and improved therapeutics. Our research focuses on immunotherapy with the aim of reinforcing our own bodies' immune system response against the spread of these tumour cells. Of particular importance to this project is Chimeric Antigen Receptor (CAR) T-Cell therapy. CAR T-Cells are a type of immune cells derived from patients' own blood, which are then genetically engineered in the laboratory to express receptors that recognize the cancer cells specifically and kill them. This therapy has shown great success in clinical trials; however, its efficacy is hampered by poor proliferation and expansion of the CAR T-Cells after re-administration into patients. In order to overcome this challenge, chemotherapeutic agents are administered beforehand to reduce the host immune cells' response against the treatment, but while also risking damage to the engineered CAR T-Cells. Therefore, our objective is to construct chemotherapy resistant CAR T-Cells and assess their proliferative capacity. Successful modifications of these cells will further enhance their expansion and persistence to ultimately improve their efficacy."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Maru, Bruktawit
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~